Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy

Pharmacogenomics

Volumn 11, Issue 9, 2010, Pages 1247-1256

  Graziano, Francesco ^a   Ruzzo, Annamaria ^b   Canestrari, Emanuele ^b   Catalano, Vincenzo ^a   Santini, Daniele ^c   Galluccio, Nadia ^b   Loupakis, Fotios ^d   Alessandroni, Paolo ^a   Spada, Daniele ^c   Ficarelli, Rita ^c   Bisonni, Renato ^c   Demidio, Silvia ^a   Vincenzi, Bruno ^c   Angeletti, Silvia ^c   Salvatore, Lisa ^d   Cremolini, Chiara ^d   Tonini, Giuseppe ^c   Falcone, Alfredo ^d   Magnani, Mauro ^b  

^a SAN SALVATORE HOSPITAL   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

gastric cancer; IGF binding protein 3; polymorphism; survival

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; GENOMIC DNA; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENT CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; SURVIVAL TIME;

AGED; DRUG THERAPY, COMBINATION; FEMALE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECURRENCE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 77957167430     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.92     Document Type: Article

References (39)

1. Wagner AD, Moehler M: Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr. Opin. Oncol. 21(4), 381-385 (2009).
2. Arkenau HT: Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J. Cancer Res. Clin. Oncol. 135(7), 855-866 (2009).
3. Schally AV, Szepeshazi K, Nagy A et al.: New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. Cell Mol. Life Sci. 61(9), 1042-1068 (2004).
4. Tao Y, Pinzi V, Bourhis J et al.: Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat. Clin. Pract. Oncol. 4(10), 591-602 (2007).
5. Zhang ZW, Newcomb PV, Moorghen M et al.: Insulin-like growth factor binding protein-3: relationship to the development of gastric pre malignancy and gastric adenocarcinoma (United Kingdom). Cancer Causes Control 15(2), 211-218 (2004).
6. Franciosi CM, Piacentini MG, Conti M et al.: IGF-1 and IGF-1BP3 in gastric adenocarcinoma. Preliminary study. Hepatogastroenterology 50(49), 297-300 (2003).
7. Yi HK, Hwang PH, Yang DH et al.: Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur. J. Cancer 37(17), 2257-2263 (2001).
8. Jiang Y, Wang L, Gong W et al.: A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin. Exp. Metastasis 21(8), 755-764 (2004).
9. Min Y, Adachi Y, Yamamoto H et al.: Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 54(5), 591-600 (2005).
10. Lee DY, Yi HK, Hwang PH et al.: Enhanced expression of insulin-like growth factor binding protein-3 sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells. Biochem. Biophys. Res. Commun. 294(2), 480-486 (2002).
11. Yamada PM, Lee KW: Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am. J. Physiol. Cell Physiol. 296(5), 954-976 (2009).
12. Jogie-Brahim S, Feldman D, Oh Y: Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr. Rev. 30(5), 417-437 (2009).
13. Guo YS, Beauchamp RD, Jin GF et al.: Insulin like growth factor-binding protein modulates the growth response to insulin like growth factor 1 by human gastric cancer cells. Gastroenterology 104(6), 1595-1604 (1993).
14. Chen W, Wang S, Tian T et al.: Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur. J. Hum. Genet. 17(12), 1668-1675 (2009).
15. Patel AV, Cheng I, Canzian F et al.: Breast and prostate cancer cohort consortium. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: fndings from the breast and prostate cancer cohort consortium (BPC3). PLoS One 3(7), E2578 (2008).
16. Canzian F, McKay JD, Cleveland RJ et al.: Polymorphisms of genes coding for insulin? like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br. J. Cancer 94(2), 299-307 (2006).
17. Cheng I, DeLellis Henderson K, Haiman CA et al.: Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J. Clin. Endocrinol. Metab. 92(9), 3660-3666 (2007).
18. Fuchs CS, Goldberg RM, Sargent DJ et al.: Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin. Cancer Res. 14(24), 8263-8269 (2008).
19. Berrigan D, Potischman N, Dodd KW et al.: Serum levels of insulin-like growth factor-I and insulin-like growth factor-I binding protein-3: quality control for studies of stored serum. Cancer Epidemiol. Biomarkers Prev. 16(5), 1017-10122 (2007).
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Statistics subcommittee of the NCI-EORTC working group on cancer diagnostics. Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer 93(4), 387-391 (2005).
21. Graziano F, Kawakami K, Ruzzo A et al.: Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. Int. J. Cancer 118(3), 628-632 (2006).
22. Santini D, Angeletti S, Ruzzo A et al.: Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin. Exp. Immunol. 154(3), 360-364 (2008).
23. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res. 16(3), 1215 (1988).
24. Laurén P: Histogenesis of intestinal and diffuse types of gastric carcinoma. Scand. J. Gastroenterol. Suppl. 180, 160-164 (1991)
25. Halperin E, Eskin E: Haplotype reconstruction from genotype data using imperfect phylogeny. Bioinformatics 20(12), 1842-1849 (2004).
26. Ross P, Nicolson M, Cunningham D et al.: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fuorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. 20(8), 1996-2004 (2002).
27. Cocconi G, Carlini P, Gamboni A et al.: Cisplatin, epirubicin, leucovorin and 5-fuorouracil (PELF) is more active than 5-fuorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann. Oncol. 14(8), 1258-1263 (2003).
28. Deal C, Ma J, Wilkin F et al.: Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J. Clin. Endocrinol. Metab. 86(3), 1274-1280 (2001).
29. Cohen P: Insulin-like growth factor binding protein-3: insulin-like growth factor independence comes of age. Endocrinology 147(5), 2109-2111 (2006).
30. Takaoka M, Kim SH, Okawa T et al.: IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Cancer Biol. Ther. 6(4), 534-540 (2007).
31. Liu B, Lee KW, Anzo M et al.: Insulin-like growth factor-bin ding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 26(12), 1811-1819 (2007).
32. Massoner P, Colleselli D, Matscheski A et al.: Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility. Endocr. Relat. Cancer 16(3), 795-808 (2009).
33. Garcia-Albeniz X, Gallego R: Prognostic role of the plasma inslulin-like growth factor (IGF) and IGF-binding protein 3 in metastatic colorectal cancer. Clin. Cancer Res. 15(16), 5288 (2009).
34. Gravalos C, Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19(9), 1523-1529 (2008).
35. Alami N, Page V, Yu Q et al.: Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm. IGF Res. 18(6), 487-496 (2008).
36. Jerome L, Alami N, Belanger S et al.: Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res. 66(14) 7245-7252 (2006).
37. Gualberto A, Pollak M: Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28(34), 3009-3021 (2009).
38. Huang F, Greer A, Hurlburt W et al.: The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 69(1), 161-170 (2009).
39. Karp DD, Pollak MN, Cohen RB et al.: Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor fgitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J. Thorac. Oncol. 4(11), 1397-1403 (2009).